Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Superhance on the ASK


Overview


Superhance® 680 is a small molecule fluorescent in vivo blood pool imaging agent. Superhance 680 enables imaging of circulation, blood vessels, vasculature, vascular leak, including that associated with early oncologic and opthalmologic lesions.


Products and catalog numbers


ProductCatalog NumberEx/Em wavelength (nm)Molecular weight (g/mol)Validated ExperimentsApplicationsStorage and Stability
Superhance 680NEV10116675/692~ 1540In vivoVascular
Cancer/Tumor
Technical Data Sheet


Using Superhance in vivo


The generally recommended procedure for in vivo imaging with Superhance 680 is administration via tail vein injection and imaging 0.5 – 24 hours post-injection.

  • For Acute Edema, we recommend imaging 3 hours post injection.
  • For IVM: 5-15 min post injection
ProductRoute of InjectionMouse Dose (25 g)Rat Dose (250 g)Blood t 1/2Tissue t 1/2Optimal imaging timeOptimal Re-injection Time (complete clearance)Route of Metabolism/ background tissueFMT& IVIS settings
Superhance 680IV4 nmol (150 uL)12-40 nmol1.5 h5 h3 h (1-3 h)96 hBladderFMT 680/700
IVIS 675/720

To determine the optimal imaging timepoint relative to agent injection, we imaged 4T1 tumor-bearing mice at different times post-Superhance 680 injection (Figure 1). Whole body images at 3 h post-injection (Figure 1A) reveal signal throughout the body (including bladder, intestines, liver, and heart) as well as in the tumor periphery.

superhance1.jpg
Figure 1. Imaging tumors. FMT and planar images show the patterns of fluorescence that occur in animals bearing tumor masses on the upper mammary fat pads. A) Whole body signal by FMT imaging. B) FMT imaging showing only tumor region fluorescence over time. Inset panels represent surface fluorescence detected by planar imaging.


Application notes and posters


  • Application note: Comparison of PerkinElmer Vascular Pre-clinical Fluorescent Imaging Agents in Oncology and Inflammation Research


Citations


Please visit our Citations Library for references using Genhance on the IVIS or on the FMT.